How has been the historical performance of Bacil Pharma?

Answer:The historical performance of Bacil Pharma shows a consistent lack of revenue generation over the years, with net sales and other operating income remaining at zero from March 2019 to March 2025. Despite this, the company has seen a significant improvement in its profit metrics, achieving a profit after tax of 0.40 crore in March 2025, a notable recovery from losses in previous years, including a loss of 3.86 crore in March 2022. The total expenditure has decreased from 3.92 crore in March 2022 to 0.25 crore in March 2025, indicating improved cost management. The company's total assets have increased dramatically from 1.27 crore in March 2024 to 25.55 crore in March 2025, primarily driven by a rise in non-current investments. Breakdown: Bacil Pharma's financial history reveals a persistent absence of sales and operating income from March 2019 through March 2025, with total operating income consistently recorded at zero. However, the company has made strides in reducing its total expenditure, which fell significantly from 3.92 crore in March 2022 to 0.25 crore in March 2025. This reduction in expenses has contributed to a turnaround in profitability, as evidenced by the profit after tax reaching 0.40 crore in March 2025, compared to substantial losses in prior years. The company's total assets have surged from 1.27 crore in March 2024 to 25.55 crore in March 2025, largely due to an increase in non-current investments, reflecting a strategic shift in asset allocation. Overall, while Bacil Pharma has not generated revenue, its improved financial management and asset growth indicate a potential for future stability.